Mechanisms of Low Levels of Apolipoprotein B

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Study Classification

OBSERVATIONAL

Study Start Date

1997-08-31

Study Completion Date

2002-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine mechanisms of low levels of apolipoprotein B.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hyperapo B and Coronary Heart Disease

NCT00005168

Cardiovascular Diseases Coronary Disease Heart Diseases +3 more

COMPLETED

Biobehavioral Predictors of Coronary Angioplasty Outcome

NCT00005554

Cardiovascular Diseases Heart Diseases Coronary Disease

COMPLETED

Epidemiology of APO- and Lipoproteins in Elderly Women

NCT00005223

Cardiovascular Diseases Heart Diseases Coronary Disease

COMPLETED

Apolipoprotein Polymorphisms and Risk of Coronary Heart Disease

NCT00005225

Cardiovascular Diseases Heart Diseases Coronary Arteriosclerosis +1 more

COMPLETED

Biobehavioral Mechanisms of Blood Pressure Regulation

NCT00005366

Cardiovascular Diseases Heart Diseases Hypertension

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

BACKGROUND:

Elevated apoB levels are associated with an increased risk of coronary heart disease. Hypobetalipoproteinemia (HBLP) is characterized by apoB levels less than the 5 percentile. Dr. Welty, the principal investigator, sequenced mutations for truncated forms of apoB-67, apoB-55 and apoB-44.4 which causes HBLP, described a kindred from the Framingham Heart Study with HBLP due to an unidentified apoB gene mutation and purified apoB-67 containing lipoprotein particles. Heterozygous apoB-67 subjects have one normal allele making apoB-100; therefore, apoB levels would be predicted to be at least 50 percent of normal; however, they are 24 percent of normal. Dr. Welty has shown that these lower than expected levels result from decreased production of VLDL apoB-100, LDL apoB-100 and apoB-67, increased catabolism of VLDL apoB-100, and increased direct removal of apoB-67 from VLDL.

DESIGN NARRATIVE:

The first aim is to locate the apoB gene mutation in the Framingham kindred. The second aim is to perform stable isotope studies in the apoB-55 and apoB-44.4 kindreds to determine if apoB metabolism for these shorter truncations is similar to that for apoB-67. In aim three, apoB-100 synthesis is studied in heterozygous apoB-70 transgenic mice. If it is 25-25 percent of normal litter mates, the mechanism for this reduction in apoB-100 levels will be studied in hepatocytes isolated from the transgenic mice. In specific aim 4, size and composition of VLDL are compared in apoB-67 subjects and controls to determine if larger size or compositional changes account for the faster catabolism of VLDL apoB-100. The study has been extended through June 2007.